Thanks, I get it now. After a quick read through, here's the problems I see with the study. First, already mentioned, no zinc with the hydroxychloriquine. Everyone claiming good results with hydroxychloriquine gives it with zinc, and a very specific form. Second, they started the study with the intent of measuring hospitalizations and deaths. The good news was that the hospitalization rate was much lower than expected, but it was so low that the sample size was too low to give statistically significant results. They calculated they needed a sample size of 6000 people to give valid results but they had fewer than 500. So they switched midstream to the much more subjective measure of overall symptom severity. In those taking hydroxychloriquine, they had 4 hospitalizations and 1 death. In those taking the placebo, they had 10 hospitalizations, (2 of which were not Covid) and 1 death. So taking hydroxychloriquine cut the hospitalization rate in half, but the sample size was too small to have statistical significance. A few tantalizing clues that hydroxychloriquine helped those that need it most-the biggest reduction in symptom severity occurred in those over 50, but that was only 23% of the participants-too few to draw conclusions. I don't see this study disproves the effectiveness of taking hydroxychloriquine early; it just highlights the need for a bigger study with more participants who are at higher risk for hospitalization. The headline could have been "Study shows 50% reduction in hospitalizations for those taking HQC" or "No statistical significance in hospitalization and death rate for those taking HQC" Both would have been technically correct.